Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 15;11(4):95-104.
eCollection 2019.

Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1

Affiliations
Review

Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1

Aryan Rafiee Zadeh et al. Int J Physiol Pathophysiol Pharmacol. .

Abstract

Multiple Sclerosis (MS) is chronic, inflammatory, a neurologic disorder of the central nervous system (CNS). Although the exact mechanisms of MS have not been yet discovered some drugs are found helpful for its treatment. These drugs which are divided into the first line, second line and third-line therapies, have demonstrated to be helpful for MS patients based on immune basic of the disease. Previous studies have been indicated that deterioration of MS condition is associated with a stronger immune system. Most of these therapies impact on the immune system and immune cells including shifting immune cell populations toward a Th2 dominant population or suppression of the immune system so that auto-reactive immune cells cannot attack myelin sheath of neurons. Beside many beneficial effects of these drugs, some adverse effects (AE) have been reported in many experiments and clinical trials among patients suffering from MS. In this review, we conclude some AEs of beta interferon, mitoxantrone, natalizumab and fingolimod, reported in different papers and we continue the rest of the drugs in second part of our review article.

Keywords: Mechanism; adverse effect; drug; multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol. 2014;32:257–81. - PubMed
    1. Zadeh AR, Farrokhi M, Etemadifar M, Beni AA. Prevalence of benign tumors among patients with multiple sclerosis. American Journal of Experimental and Clinical Research. 2015;2:127–132.
    1. Høglund RA, Maghazachi AA. Multiple sclerosis and the role of immune cells. World J Exp Med. 2014;4:27–37. - PMC - PubMed
    1. Payghani C, Khani F, Zadeh AR, Reisi P, Alaei H, Rashidi B. The effect of levothyroxine on serum levels of interleukin 10 and interferon-gamma in rat model of multiple sclerosis. Adv Biomed Res. 2017;6:118. - PMC - PubMed
    1. Rafiee Zadeh A, Ghadimi K, Mohammadi B, Naghibi S, Danaeiniya A. Effects of estrogen and progesterone on differ-ent immune cells related to multiple sclerosis. Caspian J Neurol Sci. 2018;4:39–46.

LinkOut - more resources